aNews update ASCE ...
ATTENTION INVESTING PUBLIC ASCE . PK BELLEVUE, WA. September 27th, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious Dr. Mease is Chief of the Rheumatology Clinical Research Division at Swedish Hospital, Clinical Professor at the University of Washington, and founder Our focus is SOLUTIONS through RESEARCH and DISCOVERY. Ascentia is developing and commercializing new pharmaceutical and biomedical products for Forward-Looking Statements This release may contain forward-looking statements that involve risks and uncertainties. These statements do not constitute representations or promises. Rather, these statements express opinions, hopes and desires that may not be based on objective or factual criteria or measurable results. No one should rely on such statements for any purpose except as specifically stated To get taken off the list email NOSTK@Yahoo.com
Recent Trading Range: $.80 - $.90
Expected Trading Range: $1.50 - $2.00
ASCE . PK
BELLEVUE, WA. September 14, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious
pharmaceuticals, compounds and other products, announces it has received an initial commitment for up to $1 million in funding for continued research
particularly in anti-cancer compounds and for organizational growth.
pharmaceuticals, compounds and other products, announces the addition of Dr. Philip Mease to its Scientific Advisory Board. Dr. James Clagett,
President and CEO of Ascentia said, .We are privileged to have such an internationally recognized rheumatologist who has a distinguished career in the
clinical development of therapies for rheumatic diseases. Dr. Mease.s experience in clinical drug discovery along with his respected relationship with
drug regulatory agencies will greatly assist Ascentia in its drug discovery and commercialization program..
of Seattle Rheumatology Associates. Dr. Mease graduated from Stanford University Medical School and completed his medical training at University of
Washington, Seattle.
About Ascentia Biomedical Corporation
application in a number of areas, including treatment for asthma, arthritis, psoriasis and cancer. Initially, a majority of these products will be
secured through direct purchase or through licensing. As the Company grows and evolves, more products will be developed internally. Ascentia is focused
on therapies for cancer and diseases of inflammation.



0 Comments:
Post a Comment
<< Home